Follow Us TR

News Details

Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp Psoriasis

About Arcutis Biotherapeutics, Inc.
  • NASDAQ: $ARQT
  • Notified: $29.00
  • 09:02 EDT

Price Chart